Glaxosmithkline Biologicals Sa

Novartis Ag

Gsk Vaccines S.r.l.

Roberto Adamo

Francesco Berti

Qi-Ying Hu

Paolo Costantino

Maria Rosaria Romano

Francesca Micoli

Immaculada Margarit Y Ros

Elisa Danieli

Filippo Carboni

Martin Allen

This disclosure provides novel saccharide derivatives, conjugates, and methods for making the derivatives and conjugates.

Cycloalkyne derivatized saccharides

The present invention is directed towards conjugates comprising fragments of the capsular polysaccharide of Type III Group B(GBS). Suitable fragments may be produced synthetically or by depolymerisation of native polysaccharide.

Immunogenic compositions

The invention provides a conjugate of aserogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.

Meningococcus serogroup X conjugate

The invention provides a conjugate of aserogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group in the capsular polysaccharide, to give an oxidized polysaccharide with an aldehyde group; and (b) coupling the oxidized polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.

A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain having and amino terminus end (A) and an acid terminus end (A) of the protein or polypeptide and having a weight average molecular weight equal to or greater than 10,000 Daltons (10 kDa), wherein the conjugate comprises a number m of tyrosine conjugates (modified tyrosine residues) as depicted in Formula (I-A) or (I), where m is at least one and is less than or equal to n: where X, Lg, L and R are as defined herein.

Growing community of inventors

Siena, Italy

Roberto Adamo